On December 12, Gelonghui reported that Kuanbo Medical-B (02216.HK) announced that on December 12, 2024, the Board of Directors resolved to exercise the authority under the repurchase authorization to repurchase the company's shares in the open market from time to time. The proposed share repurchase will be funded by the company's available Cash. The company will not conduct the repurchase if it would have a significant adverse impact on the company's operating capital. The company will subsequently cancel, hold in treasury, sell, or transfer the repurchased shares (if any) when deemed appropriate by the Board of Directors.

The company's current financial condition is stable. The Board of Directors believes that the current Fill Price of the shares does not reflect their intrinsic value. The Board believes that the proposed share repurchase can enhance the value of the shares, thereby increasing returns for Shareholders. Furthermore, the Board believes that the proposed share repurchase reflects the company's confidence in its long-term Business prospects and growth potential, which will ultimately benefit the company and be in the best interests of the company and Shareholders as a whole.